Microchannel Tech Cp (MCTC) 0.0017 $MCTC
BioLight Reports Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test
PR Newswire - Tue Jul 26, 6:00AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT) ("BioLight" or the "Company"

, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions and also in innovations in cancer diagnostics, announced promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.
BOLT: ()
BioLight Announces Partnership With Axella Research For CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer
PR Newswire - Mon Nov 30, 6:00AM CST
BioLight Life Sciences Investments (OTCQX:BLGTY, TASE:BOLT) ("BioLight" or the "Company"

, announced today that its cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC) ("Micromedic"

, has entered into a Collaboration Agreement (the "Agreement"

with Axella Research LLC ("Axella"

, to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.